| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Zheng-Yin Liao | Q87635713 |
| P2093 | author name string | Jie Liang | |
| Biao Yang | |||
| FangYun Yang | |||
| HongFeng Gou | |||
| ZiYu Qu | |||
| P2860 | cites work | Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma | Q84603257 |
| Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma | Q84782537 | ||
| Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial | Q84975049 | ||
| Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma | Q85064441 | ||
| Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis | Q85508799 | ||
| Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma | Q90729197 | ||
| Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials | Q93377794 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 | ||
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma | Q28314897 | ||
| Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison | Q28487597 | ||
| Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. | Q30248206 | ||
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study | Q33631372 | ||
| Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study | Q33691454 | ||
| Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. | Q33918062 | ||
| Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma | Q34089023 | ||
| Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting | Q34131801 | ||
| Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. | Q35164855 | ||
| Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis | Q35506937 | ||
| Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. | Q35658940 | ||
| Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma | Q35682000 | ||
| Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis | Q35838619 | ||
| Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis | Q36062904 | ||
| Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE) | Q36516386 | ||
| Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. | Q36673829 | ||
| Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma | Q37097620 | ||
| Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. | Q37162432 | ||
| Loco-regional treatment of hepatocellular carcinoma | Q37766546 | ||
| Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis | Q38769401 | ||
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization | Q39424036 | ||
| Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors | Q40509316 | ||
| Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. | Q40583337 | ||
| Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients | Q40893720 | ||
| Radioembolization Versus Chemoembolization (DEBDOX) for the Treatment of Unresectable Hepatocellular Carcinoma: A Propensity Matched Study | Q41005759 | ||
| A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma. | Q41439026 | ||
| Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs | Q42149776 | ||
| A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma | Q45366523 | ||
| Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. | Q45784297 | ||
| Radiographic response to yttrium-90 radioembolization in anterior versus posterior liver segments | Q47677737 | ||
| Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma | Q48058236 | ||
| Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. | Q48148835 | ||
| Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. | Q51082254 | ||
| Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. | Q51499185 | ||
| Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. | Q51768447 | ||
| Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia. | Q53025674 | ||
| Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. | Q53216812 | ||
| Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis | Q58804965 | ||
| Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) | Q83157920 | ||
| Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol | Q83371638 | ||
| A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization | Q84121312 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P304 | page(s) | e0227475 | |
| P577 | publication date | 2020-02-19 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review | |
| P478 | volume | 15 |
| Q90109763 | Correction: Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review | cites work | P2860 |
Search more.